Long noncoding RNAs in acute myeloid leukemia: biomarkers, prognostic indicators, and treatment potential.

IF 6 2区医学 Q1 ONCOLOGY Cancer Cell International Pub Date : 2025-04-05 DOI:10.1186/s12935-025-03763-5

Maryam Farajzadeh, Mehrdad Fathi, Pooya Jalali, Armin Mahmoudsalehi Kheshti, Shahla Khodayari, Mohammad Hojjat-Farsangi, Farhad Jadidi

{"title":"Long noncoding RNAs in acute myeloid leukemia: biomarkers, prognostic indicators, and treatment potential.","authors":"Maryam Farajzadeh, Mehrdad Fathi, Pooya Jalali, Armin Mahmoudsalehi Kheshti, Shahla Khodayari, Mohammad Hojjat-Farsangi, Farhad Jadidi","doi":"10.1186/s12935-025-03763-5","DOIUrl":null,"url":null,"abstract":"<p><p>Long noncoding RNAs (lncRNAs) have been recognized as significant modulators of gene expression and are essential for various biological functions, even though they don't appear to have the ability to encode proteins. Originally considered dark matter, lncRNAs have been recognized as being dysregulated and contributing to the onset, progression, and resistance to treatment of acute myeloid leukemia (AML). AML is a prevalent type of leukemia characterized by the disruption of myeloid cell differentiation, leading to an increased number of immature myeloid progenitor cells. Currently, the need for novel biomarkers and treatment targets to enhance therapeutic alternatives has led to a focus on lncRNAs as possible indicators for prognostic, therapeutic, and diagnostic systems in various human cancers, including AML. Recent research has recognized a limited set of lncRNAs as possible prognostic biomarkers or diagnoses in AML. This review evaluates the key research that highlights the significance of lncRNAs in AML and discusses their roles and impacts on the disease. Furthermore, we intend to underscore the importance of lncRNAs as new and trustworthy markers for the diagnosis, prediction, drug resistance, and targets for treatment in AML.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"131"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03763-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Long noncoding RNAs (lncRNAs) have been recognized as significant modulators of gene expression and are essential for various biological functions, even though they don't appear to have the ability to encode proteins. Originally considered dark matter, lncRNAs have been recognized as being dysregulated and contributing to the onset, progression, and resistance to treatment of acute myeloid leukemia (AML). AML is a prevalent type of leukemia characterized by the disruption of myeloid cell differentiation, leading to an increased number of immature myeloid progenitor cells. Currently, the need for novel biomarkers and treatment targets to enhance therapeutic alternatives has led to a focus on lncRNAs as possible indicators for prognostic, therapeutic, and diagnostic systems in various human cancers, including AML. Recent research has recognized a limited set of lncRNAs as possible prognostic biomarkers or diagnoses in AML. This review evaluates the key research that highlights the significance of lncRNAs in AML and discusses their roles and impacts on the disease. Furthermore, we intend to underscore the importance of lncRNAs as new and trustworthy markers for the diagnosis, prediction, drug resistance, and targets for treatment in AML.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

长链非编码rna在急性髓性白血病中的作用：生物标志物、预后指标和治疗潜力。

长链非编码rna （lncRNAs）已被认为是基因表达的重要调节剂，对各种生物功能至关重要，尽管它们似乎没有编码蛋白质的能力。lncrna最初被认为是暗物质，现已被认为是失调的，并参与急性髓性白血病（AML）的发病、进展和治疗抵抗。AML是一种常见的白血病类型，其特征是髓系细胞分化受阻，导致未成熟髓系祖细胞数量增加。目前，需要新的生物标志物和治疗靶点来增强治疗方案，这导致人们关注lncrna作为各种人类癌症（包括AML）的预后、治疗和诊断系统的可能指标。最近的研究已经认识到一组有限的lncrna可能是AML的预后生物标志物或诊断。本文综述了突出lncrna在AML中的重要意义的关键研究，并讨论了它们在AML中的作用和影响。此外，我们打算强调lncrna作为AML诊断、预测、耐药和治疗靶点的新的可靠标志物的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.